Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
We Employ a Holistic Approach to Maximize the Value of Our Medicines for Patients
|||
མ་
We DEEPLY UNDERSTAND
the medicine, the disease and
the market dynamics, investing in
clinical data to advance the science
We develop the right
COMMERCIAL STRATEGY,
TEAM AND INFRASTRUCTURE
to support our patients and
drive uptake
We develop the right
CLINICAL STRATEGY
to improve physician understanding
and clinical conviction to benefit more
patients and optimize growth
•
KRYSTEXXA exemplifies our industry-leading holistic approach; we are leveraging this expertise with TEPEZZA
KRYSTEXXA was an underperforming and undervalued asset at acquisition
in January 2016
• We transformed its growth trajectory through strong commercial
execution, quintupling annual net sales in 4 years
• We are driving continued growth opportunities for KRYSTEXXA;
projecting peak U.S. annual net sales of >$1B(1)
• We are further maximizing KRYSTEXXA through our immunomodulation
clinical strategy so more patients can benefit
(1) Horizon estimate.
HORIZON
8View entire presentation